Nanocell attack: new hope for tough pancreatic cancer?

NCT ID NCT07049055

First seen Nov 11, 2025 · Last updated May 13, 2026 · Updated 21 times

Summary

This study tests whether adding a new type of targeted nanocell therapy to standard chemotherapy can help people with metastatic pancreatic cancer live longer. The nanocells are designed to deliver a powerful drug directly to cancer cells while also boosting the immune system. About 144 adults whose cancer has worsened despite prior treatment will be randomly assigned to receive either the nanocell combo or standard chemo alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PDAC - PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Atlantic Health

    RECRUITING

    Summit, New Jersey, 07901, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Chan Soon-Shiong Institute for Medicine

    ACTIVE_NOT_RECRUITING

    El Segundo, California, 90245, United States

  • Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10032, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Taylor Cancer Center

    RECRUITING

    Maumee, Ohio, 43537, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.